The MCID of the transition dyspnea index is a total score of one unit.
about
Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysisImproving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterolEvidence for cognitive-behavioral strategies improving dyspnea and related distress in COPDClinical potential of aclidinium bromide in chronic obstructive pulmonary diseaseNew combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectivesCan roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysisA randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPDOutcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitationsRescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis.Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trialsAclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials.Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review.Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseInspiratory high frequency airway oscillation attenuates resistive loaded dyspnea and modulates respiratory function in young healthy individuals.Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patientsCorrelating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis.Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies.The longitudinal pattern of response when morphine is used to treat chronic refractory dyspneaMeasurement of breathlessness in clinical trials in patients with chronic heart failure: the need for a standardized approach: a systematic review.Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week studyNVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.Treating the small airways.Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.Minimal clinically important differences in pharmacological trials.QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease.Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.Clinical use of aclidinium in patients with COPD.Update on ultra-long-acting β agonists in chronic obstructive pulmonary disease.Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use.Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD.Patient reported outcome measures in chronic obstructive pulmonary disease: Which to use?
P2860
Q26800134-D6083D18-B12B-43B2-A71F-6EA8E3B4979FQ26851664-5F5C7877-F05A-48D5-9727-843B1E9D20B0Q27023147-264D005E-E64D-4978-A559-DB2C8CDE933FQ27023223-F58E70F4-784B-4E55-8357-31EBD39DADA8Q27024384-5AD1DEEA-9DB5-46E2-993D-ADFD0413EB00Q28070108-26CEFC1D-8F40-41CA-B5DD-DD173D5DAE6DQ28596637-2EEB92B6-5F4B-4CFE-90A7-9555EC6BEAC4Q30480535-5AB03288-36D7-400F-B21D-FFD7DA2B9028Q33651564-27A4F1A9-63A3-46D2-ACBC-F00CE9993FFDQ33824534-AC7068F7-A395-485C-972A-257E9B7EEE0AQ34336907-B932CE28-AE33-4FC2-8A66-B15E4FAA9B5AQ34544020-3D611A15-0B48-43B1-8D40-69AA3DE20FC6Q34686851-3115EA0F-CDBA-41E0-8FF6-7B4FBE90C16FQ34957303-9EF307EA-1F39-4509-8BA4-3A1B9993FF99Q34995066-A9AE66E1-59AC-4FF8-9955-057D477C3962Q35126299-2DFD4D27-35FD-42FE-B2DC-23EC4D7EDCA4Q35508579-0DCA3898-E98A-46B4-B78A-23C833633AADQ35782210-B2FC07F8-6D09-4BFF-BFC2-A2B1D473A003Q36307097-77BC6695-BCD6-4323-8A8A-B4B9DD07A904Q36329064-C1D5D626-0222-4E60-B8A1-764571FCC152Q36924015-4F21A186-15B8-48AA-A5CC-FA25C0F5337CQ36929677-03D01DFA-4C49-433A-8728-C248FECC6CF5Q37032302-229245C8-8B40-48D4-B656-C6F3015D10E1Q37677389-99DF90DF-EE45-4FB6-8375-3BB10B6BC1B6Q37682668-BCA22FBE-A487-405B-AFB7-E4F486BA8D14Q37867838-ACB0E654-0625-4295-8DD8-189BAA004BA8Q38052955-41695FAE-3FBF-40A2-87F7-8CFBCEEC5866Q38060087-81B8CF14-933A-4B20-B2F6-A824AA13F1C4Q38072277-C8E8E873-E440-41BE-A6CC-6BE11DE5211EQ38112092-403256D7-4FC0-4DBE-9C9E-52B7A551F2DEQ38137141-A9EC688E-519E-48C4-9770-352B2CB18AA4Q38175163-47A0CB59-5199-45D6-AE9D-1315739F85A0Q38194114-0ECD2BCC-3427-46DB-95DF-F02A2F8E6CF8Q38204363-87375341-E389-4335-8ABE-EBE10B4D6688Q38210538-C68987D8-D36A-4848-B30C-867025915D90Q38241442-FB5D1454-E230-4358-9813-F075079FA28EQ38258030-2F967469-6B5E-4EE8-9C64-C0BC7D4B22EDQ38303157-1134DEFC-431D-455A-8F96-1617DFC8D6AAQ38604644-7211DDEE-4B06-44D2-B2AC-5E3C270A4505Q38711045-E8FC025F-594D-43DD-A26B-FF9262650077
P2860
The MCID of the transition dyspnea index is a total score of one unit.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The MCID of the transition dyspnea index is a total score of one unit.
@ast
The MCID of the transition dyspnea index is a total score of one unit.
@en
type
label
The MCID of the transition dyspnea index is a total score of one unit.
@ast
The MCID of the transition dyspnea index is a total score of one unit.
@en
prefLabel
The MCID of the transition dyspnea index is a total score of one unit.
@ast
The MCID of the transition dyspnea index is a total score of one unit.
@en
P2860
P356
P1476
The MCID of the transition dyspnea index is a total score of one unit.
@en
P2093
Donald A Mahler
Theodore J Witek
P2860
P304
P356
10.1081/COPD-200050666
P407
P577
2005-03-01T00:00:00Z